Diabetic eye disease: The urgent need for early, non-invasive treatments
Drug Discovery World
MAY 15, 2024
Dr Catherine Beech , CEO at Exonate and Dr Pete Adamson , CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Diabetic retinal disease, termed diabetic retinopathy (DR), is a significant risk factor for people with Type I or II diabetes, and one that increases with time as patients experience repeated and continued issues with glycaemic control.
Let's personalize your content